Thromb Haemost 1984; 52(01): 081-084
DOI: 10.1055/s-0038-1661142
Original Article
Schattauer GmbH Stuttgart

Changes in Plasma Levels of Protease and Fibrinolytic Inhibitors Induced by Treatment in Acute Myeloid Leukemia

F Velasco
The Department of Haematology, “Reina Sofia” Hospital, Cordoba, Spain
,
A Torres
The Department of Haematology, “Reina Sofia” Hospital, Cordoba, Spain
,
P Andres
The Department of Haematology, “Reina Sofia” Hospital, Cordoba, Spain
,
F Martinez
The Department of Haematology, “Reina Sofia” Hospital, Cordoba, Spain
,
P Gomez
The Department of Haematology, “Reina Sofia” Hospital, Cordoba, Spain
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 02. Februar 1984

Accepted 05. Mai 1984

Publikationsdatum:
19. Juli 2018 (online)

Zoom Image

Summary

We have studied the main protease inhibitors of leukocytes, alpha-1-protease (α1-PI), alpha- 1-antichymotrypsin (α1-Achy) and alpha-2-macroglobulin (α2-M), as well as different parameters of coagulation and fibrinolysis in 21 cases of acute nonlymphoblastic leukemia (ANLL) before, during and after therapy.

Nine of the patients presented signs of DIC, 8 of whom belonged to subtype M3 and to subtype 1 M1.

The initial α1-PI and α1-Achy levels, which were elevated, increased during the treatment period. There was no significant difference between patients with and without DIC. However, those leukemic patients with DIC showed a significant decrease in plasminogen (p <0.005) and fast antiplasmin (p <0.01) only during the treatment compared with DIC free patients. All DIC cases demonstrated circulating plasmin-antiplasmin complex (P-AP) both before and during treatment.

Independent of a possible proteolytic action of leukocyte enzymes on clotting factors in the clinical course of ANLL (mainly M3 subtype), our results suggest an activation of plasminmediated fibrinolysis related to the activation of plasminogen by leukocytes, reactive DIC or both.